Language: Spanish
References: 14
Page: 49-53
PDF size: 63.29 Kb.

ABSTRACT

Introduction: Severe sepsis is defined by the association of sepsis and acute organic failure. Mortality of severe sepsis is reported between 35-45%. The annual costs associated with sepsis care have been estimated at $16.7 billion. It has been demonstrated a significantly lower mortality in patients taking protein C activated when compared with placebo. We report the results of use of protein C activated in patients with severe sepsis in Mexico. Patients and Methods: We included patients with severe sepsis, without contraindications to protein C activated, but they could not buy the drug. The patients received a 96-hour infusion of 24 µg/kg/h of protein C activated. The patients were followed until they died or were delivered. Results: We delivered protein C activated to 14 patients. The mortality in this population was 28.6% (24.7% in PROWESS). We had severe bleeding in three patients (21.4%) and we have had to discontinue the infusion in two of them. Conclusion: In this report, protein C activated showed a tendency to lower mortality in patients with severe sepsis when compared with the PROWESS placebo group, especially in patients with 2-4 organic failure and mechanical ventilation requirements.

REFERENCES

1. Members of the American College of Chest Physicians/Society of Crit Care Med Consensus Conference Committee. Definitions for the sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.

2. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-1256.

3. Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associates cost of care. Crit Care Med 2001;29:1303-1310.

4. Beutler B, Poltorak A. Sepsis and evolution of the innate immune response. Crit Care Med 2001;29:S2-S6.

5. Aird WC. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit Care Med 2001;29: S28-S34.

6. Hack CE, Zeerleder S. The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 2001;29: S21-S27.

7. Bauer PR. Microvascular responses to sepsis: Clinical significance. Pathophysiology 2002;8:141-148.

8. Grinnell BW, Joyce D. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med 2001;29:S53-S60.

9. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.

10. Vincent JL, Angus DC, Artigas A et al. Effects of the drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003;31:834-840.

11. Dhainaut JF, Laterre PF, Janes JM. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 2003;29:894-903.

12. Launois R, Franca LR, Guidet B et al. Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalized patients. Crit Care Forum 2002;6(Suppl 1):116.

13. Marlar RA, Endros-Brooks J, Miller C. Serial studies of protein C and plasma inhibitor in patients with disseminated intravascular coagulation. Blood 1985;66:59-63.

14. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:684-693.